TRIAL DETAIL
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 09/01/2007 |
Age of Trial (yrs) 17.2 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
IGF1R inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
XL228-002 |
|||
Sponsor: |
Exelixis |
|||
Patient Contact: |
Exelixis Contact Line
1-866-939-4041 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
The purpose of this study is to assess the safety and tolerability of the multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl) administered as a once- or twice-weekly 1-hour intravenous infusion in subjects with advanced malignancies. As of July 1, 2009 sites are being given ammendments 3 and 4 that limit this trial to Lung cancer, colorectal and Multiple Myeloma. UCLA has signed. Mich has the ammendments before the IRB but has not yet signed (est. in about a month). Duke has probably signed. |
|||
Trial Links |
Trial Results |
Drug Information |
| XL228 on the Exelixis website |
| A phase 1 study of XL228, a potent IGF1R / AURORA / SRC inhibitor, in patients with solid tumors or hematologic malignancies |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
10945 Le Conte Ave. |
Los Angeles |
CA |
90095 |
USA |
|
1500 East Medical Center Dr |
Ann Arbor |
MI |
48109 |
USA |
|
Durham |
NC |
27705 |
USA |
||
1365C Clifton Road |
Atlanta |
GA |
30322 |
USA |